The restructuring of Pfizer's R&D organization, with Oncology becoming a stand-alone unit, indicates a strategic focus on this area. This could potentially lead to more efficient and focused research, which could in turn lead to the development of new drugs and treatments. This could have a positive impact on Pfizer's stock in the short term, as it signals a potential for growth in a key area of the pharmaceutical industry.